Literature DB >> 18819711

Expression profile of Eph receptors and ephrin ligands in healthy human B lymphocytes and chronic lymphocytic leukemia B-cells.

Luis M Alonso-C1, Eva M A Trinidad, Beatriz de Garcillan, Monica Ballesteros, Milagros Castellanos, Ignacio Cotillo, Juan J Muñoz, Agustin G Zapata.   

Abstract

Increasing information relates some Eph receptors and their ligands, ephrins (EFN), with the immune system. Herein, we found that normal B-cells from peripheral blood (PB) and lymph nodes (LN) showed a differential expression of certain Eph/EFN members, some of them being modulated upon in vitro stimulation including EFNA1, EFNA4, EphB6 and EphA10. In contrast, PB CLL B-cells showed a more heterogeneous Eph/EFN profile than their normal PB B-cell counterparts, expressing Eph/EFN members frequently found within the LN and activated B-cells, specially EFNA4, EphB6 and EphA10. Two of them, EphB6 and EFNA4 were further related with the clinical course of CLL patients. EphB6 expression correlated with a high content of ZAP-70 mRNA and a poor prognosis. High serum levels of a soluble EFNA4 isoform positively correlated with increasing peripheral blood lymphocyte counts and lymphadenopathy. These findings suggest that Eph/EFN might be relevant in normal B-cell biology and could represent new potential prognostic markers and therapeutic targets for CLL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18819711     DOI: 10.1016/j.leukres.2008.08.010

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  13 in total

1.  Expression of Eph A4, Eph B2 and Eph B4 receptors in AML.

Authors:  Tomasz Wrobel; Joanna Pogrzeba; Ewa Stefanko; Marcin Wojtowicz; Bozena Jazwiec; Justyna Dzietczenia; Grzegorz Mazur; Kazimierz Kuliczkowski
Journal:  Pathol Oncol Res       Date:  2014-04-25       Impact factor: 3.201

2.  EphA7 Functions as Receptor on BJAB Cells for Cell-to-Cell Transmission of the Kaposi's Sarcoma-Associated Herpesvirus and for Cell-Free Infection by the Related Rhesus Monkey Rhadinovirus.

Authors:  Anna K Großkopf; Sarah Schlagowski; Bojan F Hörnich; Thomas Fricke; Ronald C Desrosiers; Alexander S Hahn
Journal:  J Virol       Date:  2019-07-17       Impact factor: 5.103

3.  Eph-ephrin bidirectional signaling comes into the context of lymphocyte transendothelial migration.

Authors:  Eva M Trinidad; Agustín G Zapata; Luis M Alonso-Colmenar
Journal:  Cell Adh Migr       Date:  2010-07-22       Impact factor: 3.405

4.  Profiling Eph receptor expression in cells and tissues: a targeted mass spectrometry approach.

Authors:  Roberta Noberini; Elena Rubio de la Torre; Elena B Pasquale
Journal:  Cell Adh Migr       Date:  2012-03-01       Impact factor: 3.405

5.  Differential gene expression in the EphA4 knockout spinal cord and analysis of the inflammatory response following spinal cord injury.

Authors:  Kathryn M Munro; Victoria M Perreau; Ann M Turnley
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

6.  Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors.

Authors:  Peter W Janes; Bettina Griesshaber; Lakmali Atapattu; Eva Nievergall; Linda L Hii; Anneloes Mensinga; Chanly Chheang; Bryan W Day; Andrew W Boyd; Philippe I Bastiaens; Claus Jørgensen; Tony Pawson; Martin Lackmann
Journal:  J Cell Biol       Date:  2011-12-05       Impact factor: 10.539

Review 7.  Harnessing the Power of Eph/ephrin Biosemiotics for Theranostic Applications.

Authors:  Robert M Hughes; Jitka A I Virag
Journal:  Pharmaceuticals (Basel)       Date:  2020-06-01

Review 8.  Emerging Roles for Eph Receptors and Ephrin Ligands in Immunity.

Authors:  Thayer K Darling; Tracey J Lamb
Journal:  Front Immunol       Date:  2019-07-04       Impact factor: 7.561

9.  EphrinA4 plays a critical role in α4 and αL mediated survival of human CLL cells during extravasation.

Authors:  Miguel A Flores; Paula Fortea; Eva M Trinidad; Dolores García; Gloria Soler; Francisco J Ortuño; Agustín G Zapata; Luis M Alonso-Colmenar
Journal:  Oncotarget       Date:  2016-07-26

10.  Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.

Authors:  Ahmed F Salem; Si Wang; Sandrine Billet; Jie-Fu Chen; Parima Udompholkul; Luca Gambini; Carlo Baggio; Hsian-Rong Tseng; Edwin M Posadas; Neil A Bhowmick; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2018-02-27       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.